高级检索
当前位置: 首页 > 详情页

Bacteroides plebeius improves muscle wasting in chronic kidney disease by modulating the gut-renal muscle axis

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 预警期刊

机构: [1]Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. [2]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. [3]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
出处:
ISSN:

关键词: Bacteroides plebeius chronic kidney disease intestinal microecology muscle wasting

摘要:
Chronic kidney disease (CKD) affects approximately 10% of the global population. Muscle atrophy occurs in patients with almost all types of CKD, and the gut microbiome is closely related to protein consumption during chronic renal failure (CRF). This study investigated the effects of Bacteroides plebeius on protein energy consumption in rats with CKD, and our results suggest that Bacteroides plebeius may combat muscle atrophy through the Mystn/ActRIIB/SMAD2 pathway. A total of 5/6 Nx rats were used as a model of muscle wasting in CKD. The rats with muscle wasting were administered Bacteroides plebeius (2 × 108  cfu/0.2 ml) for 8 weeks. The results showed that Bacteroides plebeius administration significantly inhibited muscle wasting in CKD. High-throughput 16 S rRNA pyrosequencing revealed that supplementation with Bacteroides plebeius rescued disturbances in the gut microbiota. Bacteroides plebeius could also enhance the barrier function of the intestinal mucosa. Bacteroides plebeius may modulate the gut microbiome and reduce protein consumption by increasing the abundance of probiotics and reducing damage to the intestinal mucosal barrier. Our findings suggest that Bacteroides plebeius may combat muscle atrophy through the Mystn/ActRIIB/SMAD2 pathway.© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 3 区 细胞生物学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 医学:研究与实验
第一作者:
第一作者机构: [1]Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. [2]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China. [3]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. [*1]Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. [*2]Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China and Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China. [*3]Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号